Why the study?
Does ciprofibrate improve platelet aggregation and fibrinolysis in patients with hypercholesterolaemia?
Does ciprofibrate improve platelet aggregation and fibrinolysis in patients with hypercholesterolaemia?
In a small cohort of 7 patients, ciprofibrate significantly reduced plasma fibrinogen and increased fibrinolytic activity without affecting platelet aggregation.
Answers are grounded in this paper and cite their sources.
May lower fibrinogen and enhance fibrinolysis in hypercholesterolaemia; hypothesis-generating in small cohort, larger trials needed before practice change.
The fibrinolytic and platelet effects of Ciprofibrate, a new lipid lowering drug, were studied in 7 patients with hypercholesterolaemia over a 12 week period. A significant reduction in plasma fibrinogen was noted and a lesser increase in fibrinolytic activity. However, no change in platelet aggregation was noted. As expected Ciprofibrate produced a significant hypolipidaemic effect in these patients. We have described effects of Ciprofibrate which may have potential benefits in this high risk patient group.
No takes yet. Share an insight, caveat, or question.
Simpson et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: